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Background/Aims: A controversy exists about which statin is preferable for patients with acute myocardial infarction 
(AMI), and clinical impacts of different statins according to lipophilicity have not been established.
Methods: The 1,124 patients with AMI included in the present study were divided into hydrophilic- and lipophilic-statin 
groups. In-hospital complications (defined as death, cardiogenic shock, ventricular arrhythmia, infection, bleeding, and 
renal insufficiency, and other fatal arrhythmias), major adverse cardiac events (MACE), all-cause death, re-myocardial 
infarction, re-percutaneous coronary intervention (re-PCI), and surgical revascularization were analyzed during a 1-year 
clinical follow-up.
Results: Baseline characteristics were similar between the two groups, and in-hospital complication rates showed 
no between-group differences (11.7% vs. 12.8%, p = 0.688). Although MACE at the 1- and 6-month clinical follow-ups 
occurred more in hydrophilic statin group I (1 month: 10.0% vs. 4.4%, p = 0.001; 6 month: 19.9% vs. 14.2%, p = 0.022), 
no significant difference in MACE was observed at the 1-year follow-up (21.5% vs. 17.9%, p = 0.172). Both statin groups 
showed similar efficacy for reducing serum lipid concentrations. A Cox-regression analysis showed that the use of a 
hydrophilic statin did not predict 1-year MACE, all-cause death, AMI, or re-PCI.
Conclusions: Although short-term cardiovascular outcomes were better in the lipophilic-statin group, 1-year outcomes 
were similar in patients with AMI who were administered hydrophilic and lipophilic statins. In other words, the type of statin 
did not influence 1-year outcomes in patients with AMI.
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INTRODUCTION
Statins are hydroxymethylglutaryl-CoA (HMG-CoA) 
reductase inhibitors and lipid-lowering agents used for 
various kinds of dyslipidemia. They also have beneficial 
effects in ischemic heart disease such as acute coronary 
syndrome including acute myocardial infarction (AMI) 
[1-5]. Statins have shown additional pleiotropic effects 
beyond their lipid-lowering effect; they improve endo-
thelial function, reduce inflammation and coronary 
artery thrombus, and decrease left-ventricular mass, 
blood pressure, left-ventricular fibrosis, cardiac-valve 
Received : january 9, 2011
Revised   : March 31, 2011
Accepted : jun e 10, 2011
Correspondence to Youngkeun Ahn, M.D.
The Heart Center of Chonnam National University Hospital, 671 Jebong-ro, Dong-gu, Gwangju 501-757, Korea 
Tel: 82-62-220-4764, Fax: 82-62-223-3105, E-mail: cecilyk@hanmail.net
Copyright © 2011 The Korean Association of Internal Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Kim MC, et al. Hydrophilic and lipophilic statins in AMI    295
http://dx.doi.org/10.3904/kjim.2011.26.3.294  http://www.kjim.or.kr
sclerosis, atrial fibrillation, and mortality in patients 
with diabetes and renal disease [6-11]. Consequently, 
statins are essential medical therapy for patients with 
ischemic heart disease and dyslipidemia. However, 
statins comprise many subtypes based on structural 
differences, resulting in different pharmacokinetics and 
efficacy. Although different types of statins have slightly 
different efficacy, no standard exists for selecting a statin 
in a clinical setting. Generally, statins are classified 
into hydrophilic and lipophilic groups based on tissue 
selectivity. Hydrophilic statins, such as pravastatin and 
rosuvastatin, have less tissue absorption, except for the 
liver, and fewer side effects due to lower dependence on 
the cytochrome p450 enzyme [12]. Several studies have 
compared lipophilic with hydrophilic statins in a clinical 
setting [13-15].
 In a sub-analysis of the Multicenter Study 
for Aggressive Lipid-lowering Strategy by HMG-CoA 
Reductase Inhibitors in Patients with Acute Myocardial 
Infarction (MUSASHI-AMI) database, hydrophilic 
statins were shown to be superior to lipophilic statins for 
preventing new Q-waves and reducing cardiovascular 
events in normocholesterolemic patients with AMI [13]. 
Furthermore, inflammation was attenuated by hydrophilic 
compared with lipophilic statins [14]. However, in a study 
of patients with coronary artery disease, no significant 
difference in the incidence of all-cause events was 
observed with respect to statin lipophilicity [15]. 
It has not been established which statin is preferable, 
based on lipophilicity, in patients with AMI. Therefore, 
we compared the clinical outcomes in patients with AMI 
who were administered a hydrophilic statin and those 
administered a lipophilic statin.
METHODS
Study population and statin prescription
In total, 1,124 patients diagnosed with AMI from January 
2006 to June 2008 were enrolled. All patients were statin 
naïve and were prescribed a statin during admission. The 
kind of statin was not changed during the follow-up period. 
However, dose was increased to obtain the optimal target 
range of low-density lipoprotein cholesterol (LDL-C, 70-
100 mg/dL) [16,17]. Of these patients, 317 were prescribed 
a hydrophilic statin, including rosuvastatin (90%; mean 
dosage, 10.7 mg) or pravastatin (10%, 19.3 mg), and 807 
patients received a lipophilic statin, including atorvastatin 
(53%, 16.1 mg), simvastatin (19.5%, 24.7 mg), or pitavas-
tatin (17%, 2.6 mg), based on the preference of the primary 
physician or cardiologist. The AMI diagnosis was based 
on clinical presentation, including increased levels of 
cardiac biomarkers (creatine kinase-MB, troponin-I, or 
troponin-T) and 12-lead electrocardiographic findings. 
Any of the following criteria satisfied an AMI diagnosis: 
typical rise and gradual fall (troponin) or more rapid rise 
and fall (creatine kinase-MB) of biochemical markers of 
myocardial necrosis with at least one of the following: 
1) ischemic symptoms; 2) development of pathological 
Q-waves on electrocardiogram; 3) electrocardiogram 
changes indicative of myocardial ischemia (ST-segment 
deviation); or 4) coronary artery intervention [18]. 
All laboratory data were obtained immediately after 
admission. However, the lipid panel was checked in a 
fasting state, and two-dimensional echocardiography was 
performed before discharge. Of these patients, 1,095 (97.4 
%) completed the 12-month clinical follow-up.
Coronary angiographic and procedural findings
Coronary arterial lesion type was determined according 
to the American College of Cardiology/American Heart 
Association classification. The culprit vessel of patients 
with non-ST-segment elevation MI (NSTEMI) was de-
termined by the coronary angiographic findings, 12-lead 
electrocardiogram, two-dimensional echocardiogram, and 
non-invasive stress test, if possible. In cases of STEMI, 
a 12-lead electrocardiogram was mainly used to identify 
the culprit vessel. If indicated, a percutaneous coronary 
intervention (PCI) was performed. All patients received 
100-300 mg aspirin and 300-600 mg clopidogrel as a 
loading dose before PCI. A 50-70 U/kg dose of unfraction-
ated heparin was used before or during PCI to maintain 
activated clotting time at 250-300 seconds. After PCI, 100-
300 mg aspirin and 75 mg clopidogrel were prescribed 
daily as a maintenance dose. In cases of hemodynamic 
instability, an intra-aortic balloon pump (IABP) was 
inserted to support hypotension.
In-hospital outcomes and clinical endpoints
Baseline clinical characteristics, laboratory findings, 
and procedural findings were analyzed. In-hospital 
complications including mortality, periprocedureal 
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infection, major or minor bleeding, renal insufficiency, and 
other arrhythmias such as bradycardia or supraventricular 
tachycardia were evaluated. Clinical follow-up was per-
formed at 1, 6, and 12 months. Endpoints were analyzed 
as a composite of major adverse cardiac events (MACE: 
all-cause death, recurrent MI, repeated PCI, and surgical 
revascularization), cardiac death, non-cardiac death, or 
MI, and repeated PCI. Additionally, the baseline lipid panel 
was checked, and a 1-, 6-, and 12-month follow-up lipid 
panels were checked to observe the efficacy of each statin 
type. Recurrent MI was defined as recurrent symptoms 
with new electrocardiographic changes reflecting MI or 
increased cardiac biomarkers at least twice the normal 
upper limit [19]. Repeated PCI included target-lesion 
revascularization, target-vessel revascularization (TVR), 
and non-TVR [20].
Statistical analysis
Statistical analyses were performed with SPSS version 
17.0 (SPSS Inc., Chicago, IL, USA). Continuous variables 
are presented as mean ± standard deviation, and these 
were compared using the Student t test. Categorical 
variables were analyzed by the chi-square test. A paired 
t test was performed to observe significant changes in 
serum lipid levels. Cox regression analysis was used to 
compare endpoints between the two groups. Significant 
variables in the univariate analysis ( p < 0.1) for endpoints 
were included in the Cox-regression analysis. The included 
variables were age ≥ 65 years, Killip classification ≥ 3/4 
on admission, history of diabetes mellitus, multi-vessel 
disease on coronary angiography, left main stem as a 
culprit vessel, drug-eluting stent (DES) implantation, 
ventricular arrhythmia during admission, periprocedural 
cardiogenic shock, IABP insertion, left ventricular ejection 
fraction < 40% by two-dimensional echocardiography, 
high creatinine level (≥1.5 mg/dL), and high-sensitivity 
C-reactive protein (hs-CRP) level greater than a median 
value of 0.803 mg/dL. All analyses were two tailed, and all 
variables were considered significant when the p value was 
< 0.05.
RESULTS
Clinical characteristics and procedural findings
Baseline demographic, laboratory, and clinical findings 
were similar between the two groups. Additionally, PCI 
rate (hydrophilic statin, 89.0% vs. lipophilic statin, 89.1%, 
p = 0.947), PCI with coronary stents (84.5% vs. 85.6%, 
p = 0.641), and DES implantation rate (78.0% vs. 78.1%, 
p = 0.956) were not different between the two groups. 
However, statin initiation time from admission and 
initiation rate ≤24 hours after admission was higher in the 
hydrophilic statin group (48.6% vs. 40.0%, p = 0.011) (Table 
1). No significant differences in the rate of multi-vessel 
coronary artery disease, left main stem disease, and the 
location of the culprit vessel were observed. PCI success 
rate, presenting as post-PCI thrombolysis in myocardial 
infarction flow grade ≥ 2/3, was similar between the two 
groups. However, mean stent length implanted into the 
culprit vessel was longer in the lipophilic statin group (23.7 
± 5.5 mm vs. 24.6 ± 5.8 mm, p = 0.016) (Table 2).
In-hospital outcomes and endpoints during clini-
cal follow-up
The rates of in-hospital complications were similar 
between the hydrophilic group and  lipophilic group (11.7% 
vs. 12.8%, p = 0.688). During the 12-month clinical follow-
up, 210 endpoints were identified (18.9% of all patients). 
Although 1- and 6-month MACE rates were higher in 
the hydrophilic statin group, the 12-month MACE rate 
was not different between the hydrophilic group and   
lipophilic group (21.5% vs. 17.9%, p = 0.172). No difference 
was observed for repeated PCI between the two groups. 
However, death and MI rate were higher in the hydrophilic 
statin group at the 12-month follow-up based on a crude 
analysis (10.0% vs. 6.2%, p = 0.039) (Table 3). The levels 
of LDL-C, high-density lipoprotein-cholesterol (HDL-C), 
triglyceride (TG), and total cholesterol (TC) were similar 
between the two groups at the 1-, 6-, and 12-month follow-
ups (Fig. 1). None of the statins changed the levels of serum 
HDL-C or TG. However, they reduced the levels of LDL-C 
and TC at the 12-month follow-up (LDL-C, p < 0.001 and 
TC, p < 0.001, respectively).
Multivariate analysis for MACE
After adjusting for confounding factors, the hydrophilic 
statins did not predict cumulative MACE (hazard ratio 
[HR], 1.29; 95% confidence interval [CI], 0.93-1.80; p = 
0.122), all-cause death or MI (HR, 1.32; 95% CI, 0.73 to 
2.34; p = 0.352), and repeated PCI (HR, 1.10; 95% CI, 0.73 
to 1.63; p = 0.655) (Table 4 and Figs. 2-4). Results of the Kim MC, et al. Hydrophilic and lipophilic statins in AMI    297
http://dx.doi.org/10.3904/kjim.2011.26.3.294  http://www.kjim.or.kr
1-year multivariate analysis for MACE are presented in 
Table 5.
DISCUSSION
No differences were observed in the 12-month clini-
cal outcomes in patients with AMI based on statin lipo-
philicity. Few clinical and basic studies have compared 
hydrophilic and lipophilic statins. Two studies could not 
demonstrate which type of statin was better in an AMI 
setting [13,15]. In a study comparing the two types of 
statins, cognitive impairment associated with statins 
use in 24,595 patients was significantly different in the 
two types of statins. Moreover, the lipophilic, but not the 
hydrophilic, statin induced cell death in gynecological 
cancers expressing high levels of HMG-CoA reductase, 
and enhanced phagocytosis in human peripheral blood 
[21-23]. Similarly, clinical and basic studies have not 
standardized which statin type is preferable. Therefore, 
our study was designed to compare the clinical outcomes 
between the two types of statin in patients with AMI.
In our study, more patients were prescribed a hydrophilic 
than a lipophilic statin within 24 hours after admission. 
Although controversy remains, early statin therapy 
has been reported to improve cardiovascular outcome 
in patients with AMI [4,24]. However, the univariate 
analysis in our study did not show that early statin therapy 
influenced clinical outcome. Additionally, the prevalence 
of dyslipidemia on admission was relatively low in our 
Table 1. Baseline demographic, laboratory, and clinical findings 
Hydrophilic statin (n = 317) Lipophilic statin (n = 807) p value
Age, yr   65.2 ± 12.3    64.1 ± 12.7 0.206
Male 237 (74.8) 575 (71.3) 0.267
Killip class III/IV 31 (9.8) 88 (10.9) 0.667
Prior history of CAD 30 (9.5) 90 (11.2) 0.453
Hypertension 144 (45.4) 363 (45.0) 0.894
Diabetes mellitus  86 (27.1) 217 (26.9) 0.941
Smoking 208 (65.6) 524 (64.9) 0.889
Dyslipidemia 13 (4.1) 29 (3.6) 0.727
Familial history of CAD 14 (4.4) 49 (6.1) 0.315
Left ventricular EF, %  55.8 ± 11.8  55.2 ± 11.8 0.518
sT-segment elevation MI 219 (69.1) 538 (66.7) 0.480
Patients underwent PCI 282 (89.0) 719 (89.1) 0.947
  PCI with coronary stents 268 (84.5) 691 (85.6) 0.641
  Drug-eluting stent 209 (78.0) 540 (78.1) 0.956
Serum creatinine, mg/dL   1.09 ± 1.10    1.07 ± 0.79 0.732
Troponin-I, mg/dL   54.9 ± 77.2     57.7 ± 109.6 0.639
Random plasma glucose, mg/dL 174.2 ± 77.1 170.1 ± 79.0 0.425
N-terminal pro BNP, pg/mL  2,246.5 ± 5145.8  2,516.5 ± 5312.3 0.441
High sensitivity CRP, mg/dL   2.39 ± 3.94  2.34 ± 3.76 0.823
statin initiation time from admission
  ≤ 24 hr after admission 154 (48.6) 323 (40.0) 0.011
  ≤ 48 hr after admission 258 (81.4) 657 (81.4) 0.925
ACE inhibitor or ARB 279 (88.0) 731 (90.6) 0.227
Beta-blocker 265 (83.6) 701 (86.9) 0.182
Values are presented as mean ± SD or number (%).
CAD, coronary artery disease; EF, ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; BNP, B-type 
natriuretic peptide; CRP, C-reactive protein; ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker.298    The Korean Journal of Internal Medicine Vol. 26, No. 3, september 2011
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registry. This might be associated with enrollment of 
statin naïve patients. In our study, both statin groups had 
reduced serum LDL-C and TC at the 12-month follow-up. 
The TC-lowering effect was considered secondary to the 
LDL-C-lowering effect. Although statins do not influence 
the levels of serum HDL-C and TG, they reduce LDL-C [12]. 
Table 2. Angiographic findings and procedural characteristics
Hydrophilic statin (n = 317) Lipophilic statin (n = 807) p value
Multivessel CAD 132 (44.7) 340 (45.6) 0.836
Left main disease 15 (5.1) 48 (6.4) 0.472
Culprit vessel
Left anterior descending 144 (48.8) 357 (47.9) 0.836
Right coronary artery 104 (35.3) 257 (34.5) 0.829
Left circumflex artery   43 (14.6) 116 (15.6) 0.774
Left main   4 (1.4) 15 (2.0) 0.612
Type B2/C coronary lesion  211 (71.5) 537 (72.1) 0.878
Pre-PCI TIMI flow grade 0  131 (44.4) 333 (44.7) 0.945
Post-PCI TIMI flow grade 2/3   285 (96.6) 731 (98.1) 0.169
stent length, mm   23.7 ± 5.53 24.6 ± 5.83 0.016
stent diameter, mm 3.23 ± 0.41 3.24 ± 0.42 0.675
IABP insertion 13 (4.1) 31 (3.8) 0.865
Values are presented as number (%).
CAD, coronary artery disease; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; IABP, intra-aortic 
ballooning pump.







Complications 37 (11.7) 103 (12.8) 0.688
In-hospital mortality 3 (0.9) 6 (0.7) 0.718
Ventricular arrhythmia 8 (2.5) 26 (3.2) 0.699
Cardiogenic shock 21 (6.6) 40 (5.0) 0.305
1-mon outcomes
Major adverse cardiac outcomes 31 (10.0) 35 (4.4) 0.001
All-cause death or MI 25 (8.0) 22 (2.7)  < 0.001
Repeated PCI 6 (1.9) 10 (1.2) 0.405
6-mon outcomes
Major adverse cardiac outcomes 62 (19.9) 114 (14.2) 0.022
All-cause death or MI 30 (9.6) 36 (4.5) 0.002
Repeated PCI 31 (10.1) 75 (9.4) 0.573
12-mon outcomes
Major adverse cardiac outcomes 67 (21.5) 143 (17.9) 0.172
All-cause death or MI 31 (10.0) 50 (6.2) 0.039
Repeated PCI 35 (11.3) 87 (10.9) 0.750
Values are presented as number (%).
MI, myocardial infarction; PCI, percutaneous coronary intervention.Kim MC, et al. Hydrophilic and lipophilic statins in AMI    299
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The 12-month lipid profiles appeared worse than those at 
6 months. However, longer follow-up periods and larger-
scale studies are needed to confirm this issue. Short-
term MACE occurred more frequently in the hydrophilic-
statin group. Variables not included in our registry such as 
cardiopulmonary resuscitation, symptom-to-door time, 
staged PCI, and door-to-PCI time may have influenced 
these results. After correcting for confounding factors, the 
Cox regression analysis of different rates of death or MI 
at the 12-month follow-up revealed no difference between 
the two groups.
We conducted a subgroup analysis by the presence 
of ST-segment elevation. No differences in baseline 
characteristics and cardiovascular risks were observed in 
757 patients with STEMI in our registry. Clinical endpoints 
showed a similar tendency compared with the total AMI 
group analysis. The 12-month composite MACE, death or 
MI, and repeated PCI rates were also similar between the 
Table 4. Adjusted 12-mon clinical outcomes for hydrophilic statins compared with lipophilic statins
12-mon clinical outcomes
                  Unadjusted             Adjusted
OR (95% CI) p value OR (95% CI) p value
Cumulative MACEs 1.26 (0.94-1.68) 0.125 1.29 (0.93-1.80) 0.122
All-cause death or MI 1.64 (1.05-2.57) 0.030 1.32 (0.73-2.34) 0.352
Repeated PCI 1.08 (0.73-1.59) 0.706 1.10 (0.73-1.63) 0.655
OR, odds ratio; CI, confidence interval; MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary 
intervention.
Figure 1. Changes in the lipid panel at follow-up (solid line, lipophilic-statin group; dotted line, hydrophilic-statin group. p value 
represents the statistical difference between the lipid values of the hydrophilic- and lipophilic-statin groups). HDL, high-density 
lipoprotein; LDL, low-density lipoprotein.300    The Korean Journal of Internal Medicine Vol. 26, No. 3, september 2011
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two groups (Table 6). hs-CRP is a marker for inflammation 
and is associated with adverse cardiovascular outcomes 
[25]. In a subgroup analysis of 535 patients with high hs-
CRP (greater than the median value of 0.803 mg/dL), no 
differences in 12-month clinical endpoints were observed 
(Table 7).
Our study had several limitations. First, selection bias 
may have been present because of the retrospective nature 
of the study. Second, although we included as many 
variables as possible, other variables may have affected 
our results. For example, undergoing cardiopulmonary 
resuscitation, symptom-to-intervention time, and high 
statin loading dose may have affected the clinical results. 
Third, statin selection was not standardized; it was the 
decision of the physician or cardiologist. Fourth, side 
effects of statin therapy such as myopathy or hepatotoxicity 
were not compared between the two groups. Fifth, we 
could not collect detailed information about all-cause 
death or MI. Because the differences in the 1- and 6-month 
clinical outcomes between the two groups were mainly 
caused by differences in all-cause death and MI, we 
should have had detailed information about death and MI. 
Finally, reducing periprocedural MI is a current issue for 
statin therapy, and statin use is associated with a reduced 
rate of periprocedural MI [26]. However, the subjects in 
our study had AMI but not angina. Consequently, it was 
difficult to compare the periprocedural MI rate between 
the two groups; thus, a large-scaled randomized controlled 
trial will be needed.
In conclusion, although, short-term cardiovascular 
outcomes were better in the lipophilic-statin group, long-






























































Figure 2. Major adverse cardiac event (MACE)-free survival 
rates during follow-up.

































Figure 4. Repeated percutaneous coronary intervention 
(RePCI)-free survival rates during follow-up.Kim MC, et al. Hydrophilic and lipophilic statins in AMI    301
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Age, yr 64.2 ± 12.5 65.0 ± 12.6 0.423
Male  166 (75.8) 401 (74.5) 0.782
Hypertension   91 (41.6) 232 (43.1) 0.746
Diabetes mellitus   55 (25.1) 134 (24.9) 0.952
Smoking  149 (68.0) 363 (67.5) 0.932
Dyslipidemia   6 (2.7) 18 (3.3) 0.820
Left ventricular EF, % 55.2 ± 12.1 53.9 ± 11.7 0.173
Drug-eluting stent  148 (75.9) 379 (77.8) 0.614
Periprocedural cardiogenic shock  17 (7.8) 31 (5.8) 0.325
1-mon outcomes
Major adverse cardiac outcomes   22 (10.1) 23 (4.3) 0.004
All-cause death or MI  17 (7.8) 16 (3.0) 0.005
Repeated PCI    5 (2.3)   5 (0.9) 0.163
6-mon outcomes
Major adverse cardiac outcomes     42 (19.4)   81 (15.2) 0.159
All-cause death or MI  20 (9.2) 28 (5.2) 0.049
Repeated PCI   22 (10.2) 51 (9.6) 0.686
12-mon outcomes
Major adverse cardiac outcomes   47 (21.7) 101 (18.9) 0.418
All-cause death or MI   21 (9.7) 37 (6.9) 0.227
Repeated PCI   26 (12.0)   61 (11.4) 0.803
Values are presented as mean ± SD or number (%).
STEMI, ST-segment elevation myocardial infarction; EF, ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary 
intervention.




Age ≥ 65 1.22 (0.88-1.68) 0.241
Killip class ≥ 3  1.19 (0.72-1.95) 0.494
Diabetes mellitus 1.05 (0.75-1.47) 0.767
Multivessel disease 1.41 (1.02-1.96) 0.040
Left main as culprit vessel 1.66 (0.92-3.01) 0.094
DES implantation 0.65 (0.47-0.90) 0.010
Ventricular arrhythmia 0.73 (0.33-1.60) 0.433
Cardiogenic shock 1.77 (0.87-3.62) 0.118
IABP implantation 1.59 (0.77-3.30) 0.214
LV ejection fraction ≤ 40% 1.43 (0.94-2.18) 0.098
High creatinine level (≥ 1.5 mg/dL) 1.06 (0.70-1.58) 0.795
High hs-CRP level (> 0.803 mg/dL) 1.53 (1.09-2.14) 0.015
Hydrophilic statin  1.29 (0.93-1.80) 0.933
MACE, major adverse cardiac events; DES, drug-eluting stent; IABP, intra-aortic balloon pump; LV, left ventricle; hs-CRP, high sensitivity 
C-reactive protein.302    The Korean Journal of Internal Medicine Vol. 26, No. 3, september 2011
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lipophilic-statin groups in patients with AMI. In other 
words, statin type did not influence long-term outcomes in 
patients with AMI.
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Age, yr 66.6 ± 12.4  67.3 ± 12.0 0.574
Male 105 (73.9) 277 (70.5) 0.451
Hypertension 75 (52.8) 194 (49.4) 0.494
Diabetes mellitus 43 (30.3) 125 (31.8) 0.753
Smoking 92 (64.8) 253 (64.4) 0.930
Dyslipidemia 6 (4.2) 13 (3.3) 0.602
N-terminal pro BNP, pg/mL 3,418.9 ± 6,133.6 3,880.9 ± 6,611.5 0.456
Left ventricular EF, %   51.8 ± 12.4  51.9 ± 12.1 0.865
Drug-eluting stent 90 (74.4) 261 (76.1) 0.713
Periprocedural cardiogenic shock 16 (11.3) 32 (8.1) 0.304
1-mon outcomes
Major adverse cardiac outcomes 18 (12.9) 24 (6.2) 0.017
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